The current development of CNS drug research
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In the past few years, several high profiled pharmaceutical companies have decided to shut down major research activities within the central nervous system (CNS) area. For example, in December 2011 Novartis announced that the company is closing its neuroscience facility in Basel, Switzerland, where Novartis is headquartered (Abbott, 2011). It follows similar moves by GlaxoSmithKline and AstraZeneca, both based in the UK, which in 2010 announced the closure of major parts of their neuroscience research divisions globally (Jack, Financial Times, 4 February 2010). Also companies primarily based in the USA, Pfizer and Merck, as well as the French company Sanofi, have pulled back on research into brain disorders. This development is still proceeding, as e.g. AstraZeneca closed their CNS/pain centres (Fiercebiotech, press release, 2 February 2012). Several of the companies have launched smaller new initiatives based on studies of genetics and biomarkers, but as mental disorders such as unipolar depression impose the largest disease burden worldwide, e.g. 6.2% disability-adjusted life year of total (WHO, 2008), and current treatments do not work particularly well for many patients, this has obviously raised a number of concerns related to how the future developments should be carried out, and whether the genetic approach may be sufficient. In June 2012, the International College of Neuropsychopharmacology (http://www.cinp.org) hosted an international workshop in order to discuss and consider the consequences and implications of the withdrawal of these research activities. This paper presents the problem background together with a summary of the viewpoints of the invited speakers and recommendations for future intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 3×
“Wittchen et al. (2011) concluded that every year over one-third of the total EU Address for correspondence: Professor G. Wegener, Department of Clinical Medicine, Aarhus University, Skovagervej 2, DK-8240 Risskov, Denmark.”
BackgroundInfluentialHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Grand challenges in global mental health
Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., Bordin, I. A., Costello, E. J., Durkin, M., Fairburn, C., et al. (2011) · Nature · doi:10.1038/475027a · Cited by 2,043
Lyssenko, V., Nagorny, C. L. F., Erdos, M. R., Wierup, N., Jonsson, A., Spégel, P., Bugliani, M., Saxena, R., Fex, M., Pulizzi, N., et al. (2009) · Nature Genetics · doi:10.1038/ng.288 · Cited by 742
Hyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260
Neuroscience, Clinical Evidence, and the Future of Psychiatric Classification in DSM-5
Kupfer, D. J., & Regier, D. A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020219 · Cited by 245
Cited by
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Activated microglia targeting dendrimer–minocycline conjugate as therapeutics for neuroinflammation.
Sharma, R., Kim, S.-Y., Sharma, A., Zhang, Z., Kambhampati, S. P., Kannan, S., & Kannan, R. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00569 · Cited by 100
“12 Although, the primary mechanism of action of minocycline for the neuroprotective effect is not clear, it exerts biological effect via direct antagonism of multiple mechanisms including: (1) the inhibition of microglial activation, which results in suppression of proinflammatory mediators; (2) the reduction of apopt…”
BackgroundAbdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F. (2018) · Chronic Stress · doi:10.1177/2470547018796102 · Cited by 70
“Central nervous system (CNS) drug development is increasingly challenging with high failure rates in large clinical trials, and many stakeholders abandoning their CNS division or significantly reducing their clinical trials funding.(8) High failure rates are especially relevant to depression research considering the u…”
Nitric oxide signalling and antidepressant action revisited
Joca, S. R. L., Sartim, A. G., Roncalho, A. L., Diniz, C. F. A., & Wegener, G. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02987-4 · Cited by 63
Self-citation
Metadata
- Authors
- Wegener, G., & Rujescu, D.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-01
- Volume
- 16
- Issue
- 7
- Pages
- 1687-1693
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2166890356
- Cited by
- 73
- References
- 6
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The current development of CNS drug research. https://app.cochat.ai/papers/10.1017/s1461145713000345
- The paper
- Wegener, G., & Rujescu, D. (2013). The current development of CNS drug research. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145713000345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.